Actively Recruiting
Open-label Trial Evaluating Lucerastat Safety and Efficacy in Untreated Adult Male Fabry Disease Patients
Led by Idorsia Pharmaceuticals Ltd. · Updated on 2026-11-03
16
Participants Needed
16
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how well lucerastat works and how safe it is in adult male participants with Fabry disease who have not received prior treatment. The main focus is to see if lucerastat affects the amount of globotriaosylceramide Gb3, a fatty substance that accumulates in the kidneys, in these men. This is an open-label, single-arm study, meaning all participants will receive the study drug and know what they are taking. Participants will take lucerastat capsules twice daily, with doses ranging from 250 mg to 1000 mg based on their kidney function measured by estimated glomerular filtration rate eGFR. The treatment period lasts 18 months. Participants will have kidney biopsies at the start and end of the trial to assess Gb3 levels. They will also visit the clinic 10 times for check-ups and tests during the study, which can last up to 21 months in total. During the trial, participants will be monitored through regular clinic visits that include medical check-ups and laboratory tests. The primary outcome is the change in kidney Gb3 inclusions from baseline to 18 months. Plasma Gb3 concentration is also measured as a secondary outcome. The trial includes safety monitoring and assessments to track how participants respond to lucerastat over time.
CONDITIONS
Brief Title
A Study to Learn How Well Lucerastat Works and How Safe it is in Untreated Adult Male Participants With Fabry Disease
Research Team
C
Clinical Trial Information USA
C
Clinical Trial Information Europe
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here